Loading...
Market
How many new drugs will Monopar announce by end of 2025?
2
Monopar Therapeutics•Alexion Pharmaceuticals•AstraZeneca Rare Disease•Wilson Disease•Monopar•ALXN•Phase•Alexion•AstraZeneca
Resolution / Starting Odds
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Official announcements from Monopar Therapeutics
Story
Monopar Therapeutics Stock Surges 137% After Agreement for ALXN-1840, Phase 3 Drug for Wilson Disease
Oct 24, 2024, 04:08 PM
Monopar Therapeutics (NASDAQ: MNPR) has announced a significant agreement with Alexion Pharmaceuticals and AstraZeneca Rare Disease for its late-stage drug candidate targeting Wilson Disease. Following the announcement, Monopar's stock surged approximately 137%, prompting a trading halt due to volatility. The agreement grants Monopar an exclusive worldwide license to ALXN-1840, a drug candidate for Wilson Disease that has already completed a Phase 3 clinical trial. The stock was up about 20% ahead of Thursday's trading session, reflecting investor optimism regarding the potential of the drug and the strategic collaboration with Alexion and AstraZeneca.
View original story
Similar markets
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
1 therapy • 25%
2 therapies • 25%
3 therapies • 25%
More than 3 therapies • 25%
0 new indications • 33%
1 new indication • 33%
2 or more new indications • 34%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 to 2 • 25%
3 to 5 • 25%
6 to 8 • 25%
More than 8 • 25%
None • 25%
1 to 2 • 25%
3 to 4 • 25%
More than 4 • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%